Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4)

Lana M Chahine; Thomas G Beach; Nicholas Seedorff; Chelsea Caspell-Garcia; Christopher S Coffey; Michael Brumm; Charles H Adler; Geidy E Serrano; Carly Linder; Sherri Mosovsky; Tatiana Foroud; Holly Riss; Dixie Ecklund; John Seibyl; Danna Jennings; Vanessa Arnedo; Lindsey Riley; K D Dave; Brit Mollenhauer; Systemic sSynuclein Sampling study

doi:10.3233/JPD-181434

Back

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4)

Journal article

Open access

Peer reviewed

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4)

Lana M Chahine, Thomas G Beach, Nicholas Seedorff, Chelsea Caspell-Garcia, Christopher S Coffey, Michael Brumm, Charles H Adler, Geidy E Serrano, Carly Linder, Sherri Mosovsky, …

Journal of Parkinson's disease, Vol.8(4), pp.517-527

2018

DOI: 10.3233/JPD-181434

PMCID: PMC6226302

PMID: 30248065

Files and links (1)

url

https://doi.org/10.3233/JPD-181434View

Published (Version of record) Open Access

Abstract

α-synuclein is a lead Parkinson's disease (PD) biomarker. There are conflicting reports regarding accuracy of α-synuclein in different tissues and biofluids as a PD biomarker, and the within-subject anatomical distribution of α-synuclein is not well described. The Systemic Synuclein Sampling Study (S4) aims to address these gaps in knowledge. The S4 is a multicenter, cross-sectional, observational study evaluating α-synuclein in multiple tissues and biofluids in PD and healthy controls (HC). To describe the baseline characteristics of the S4 cohort and safety and feasibility of this study. Participants underwent motor and non-motor clinical assessments, dopamine transporter SPECT, biofluid collection (cerebrospinal fluid, saliva, and blood), and tissue biopsies (skin, sigmoid colon, and submandibular gland). Biopsy adequacy was determined based on presence of adequate target tissue. Tissue sections were stained with the 5C12 monoclonal antibody against unmodified α-synuclein. All specimens were acquired and processed in a standardized manner. Adverse events were systematically recorded. The final cohort consists of 82 participants (61 PD, 21 HC). In 68 subjects (83%), all types of specimens were obtained but only 50 (61%) of subjects had all specimens both collected and evaluable for α-synuclein. Mild adverse events were common, especially for submandibular gland biopsy, but only 1 severe adverse event occurred. Multicenter tissue and biofluid sampling for α-synuclein is feasible and generally safe. S4 will inform understanding of the concurrent distribution of α-synuclein pathology and biomarkers in biofluids and peripheral nervous system in PD.

Biomarkers

Parkinson’s disease

needle biopsy

synucleins

Details

Title: Subtitle: Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4)
Creators: Lana M Chahine - Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
Thomas G Beach - Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA
Nicholas Seedorff - Department of Biostatistics, The University of Iowa, Iowa City, IA, USA
Chelsea Caspell-Garcia - Department of Biostatistics, The University of Iowa, Iowa City, IA, USA
Christopher S Coffey - Department of Biostatistics, The University of Iowa, Iowa City, IA, USA
Michael Brumm - Department of Biostatistics, The University of Iowa, Iowa City, IA, USA
Charles H Adler - Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
Geidy E Serrano - Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA
Carly Linder - Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
Sherri Mosovsky - Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
Tatiana Foroud - Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
Holly Riss - Department of Biostatistics, The University of Iowa, Iowa City, IA, USA
Dixie Ecklund - Department of Biostatistics, The University of Iowa, Iowa City, IA, USA
John Seibyl - Institute for Neurodegenerative Disorders, New Haven, CT, USA
Danna Jennings - Denali Therapeutics, San Francisco, CA, USA
Vanessa Arnedo - The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA
Lindsey Riley - The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA
K D Dave - The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA
Brit Mollenhauer - Paracelsus-Elena-Klinik, Kassel and University Medical Center Goettingen, Goettingen, Germany
Systemic sSynuclein Sampling study
Resource Type: Journal article
Publication Details: Journal of Parkinson's disease, Vol.8(4), pp.517-527
DOI: 10.3233/JPD-181434
PMID: 30248065
PMCID: PMC6226302
NLM abbreviation: J Parkinsons Dis
ISSN: 1877-7171
eISSN: 1877-718X
Language: English
Date published: 2018
Academic Unit: Biostatistics
Record Identifier: 9984214853402771

Metrics

10 Record Views

19 Times Cited - Web of Science